Company news
Replicel Life Sciences Inc. (OTC:REPCF) news
Replicel Life Sciences Inc. news releases on 6ix. Latest, Apr 9, 2016: RepliCel Life Sciences Applies to Amend Warrant Exercise Price and Extend Warrant…
Press releases — page 2
RepliCel Life Sciences Applies to Amend Warrant Exercise Price and Extend Warrant Expiry Dates
April 8, 2016
RepliCel Life Sciences Announces Restructuring, Cost Reductions and Closing of Private Placement
April 6, 2016
RepliCel Life Sciences Inc. Announces Closing of Warrant Incentive Program
February 26, 2016
RepliCel Announces CEO Update
February 16, 2016
RepliCel Receives European Patent for its Innovative Dermal Injector Technology
January 11, 2016
RepliCel Life Sciences Inc. Announces Closing of Second Tranche of Private Placement
December 24, 2015
RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin
December 17, 2015
RepliCel Life Sciences Announces Leadership Transition
December 16, 2015
RepliCel Life Sciences Inc. Announces Closing of First Tranche of Private Placement
November 23, 2015
RepliCel Executives to Present at 9th World Congress for Hair Research in Miami
November 12, 2015
RepliCel Selected as One of This Year's Top 20 Public Canadian Technology Companies
November 4, 2015
RepliCel Life Sciences Inc. Announces Brokered Private Placement
October 20, 2015
First Participants Enrolled in RepliCel's Phase 1 Clinical Trial of its RCS-01 Dermatology Injectable
October 20, 2015
Industry Leader Geoff MacKay Joins RepliCel Life Sciences' Board of Directors
October 15, 2015
RepliCel Announces October Presentation and Partnering Meeting Schedule
October 8, 2015
RepliCel Presenting at Two Upcoming Investment and Partnering Forums
September 23, 2015
RepliCel Life Sciences Announces Initiation of Clinical Site and Participant Recruitment for European Skin Aging Study
September 15, 2015
BioWatch's Alan Leong Interviewed by The Life Sciences Report
September 10, 2015
RepliCel Life Sciences Cleared to Initiate Clinical Trial of RCS-01 for Dermal Rejuvenation
September 1, 2015
RepliCel Reports Second Quarter 2015 Financial Results
August 28, 2015
RepliCel Presenting at InvestMNT Investor Conference in Minneapolis
August 3, 2015
RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype
July 29, 2015
RepliCel Receives Two Important Approvals for Dermal Rejuvenation Clinical Trial
July 21, 2015
RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis
June 30, 2015
RepliCel Life Sciences Inc. Announces Closing of Brokered and Non-brokered Private Placement
June 26, 2015
RepliCel Life Sciences Announces Participation in 23rd World Congress of Dermatology, Vancouver, BC
June 5, 2015
RepliCel Life Sciences Announces Brokered Private Placement
May 31, 2015
RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference
May 21, 2015
RepliCel Life Sciences Selected to Present at Cavendish Global Health Impact Forum
May 7, 2015
RepliCel Announces 2014 Fourth Quarter and Year-End Financial Results
April 29, 2015
RepliCel Life Sciences Receives Approval to Conduct Clinical Trial for Patients with Chronic Achilles Tendinosis
April 15, 2015
RepliCel Life Sciences Receives TSX Venture Exchange Approval to Extend Warrant Expiry Dates
April 7, 2015
RepliCel Life Sciences Applies to Extend Warrant Expiry Dates
April 2, 2015
RepliCel Life Sciences in Japan for Key Industry Meetings
March 12, 2015
RepliCel Submits Clinical Trial Application for its Dermatological Product
February 23, 2015